Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 11/20 | 0.38 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | PADI4 | Q9UM07 | 2/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27482656 | 0.83 | FOLH1 (0.41) | FOLH1CYP19A1CYP1A1PADI4DPP4 | |
| SCHEMBL956921 | 0.82 | EGLN3 (0.46) | FOLH1CYP19A1CYP1A1 | |
| SCHEMBL1179084 | 0.80 | FOLH1 (0.39) | FOLH1CYP19A1CYP1A1DPP4 | |
| SCHEMBL10065548 | 0.79 | TSHR (0.41) | FOLH1CYP19A1CYP1A1ALDH1A1 | |
| SCHEMBL3586469 | 0.79 | — | — | |
| SCHEMBL28495152 | 0.78 | FOLH1 (0.38) | FOLH1CYP19A1CYP1A1PADI4DPP4 | |
| SCHEMBL14578732 | 0.76 | CYP19A1 (0.42) | FOLH1CYP19A1CYP1A1ALDH1A1 | |
| SCHEMBL11361006 | 0.75 | CYP19A1 (0.48) | FOLH1CYP19A1CYP1A1ALDH1A1DPP4 | |
| Propionic Acid SCHEMBL28759037 | 0.73 | KDM4E (0.41) | FOLH1CYP19A1CYP1A1ALDH1A1 | |
| SCHEMBL12019278 | 0.73 | MAPK1 (0.44) | FOLH1CYP19A1ALDH1A1PADI4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1054865-A1 | FARNESYL TRANSFERASE INHIBITORS | AstraZeneca UK Limited (GB) | 2000-11-29 | — | — | EP | claimed |
| WO-1999041235-A1 | FARNESYL TRANSFERASE INHIBITORS | ASTRAZENECA UK LIMITED (GB) | 1999-08-19 | — | — | WO | claimed |
| EP-3793565-B1 | MCL-1 INHIBITORS | GILEAD SCIENCES INC (US) | 2022-01-05 | — | — | EP | disclosed |
| US-10703733-B2 | MCL-1 inhibitors | GILEAD SCIENCES, INC. (US) | 2020-07-07 | — | — | US | disclosed |
| US-20190352271-A1 | MCL-1 INHIBITORS | GILEAD SCIENCES, INC. | 2019-11-21 | — | — | US | disclosed |
| US-20160083356-A1 | FUNCTIONALIZED 4- AND 5-VINYL SUBSTITUTED REGIOISOMERS OF 1, 2, 3-TRIAZOLES VIA 1, 3- DIPOLAR CYCLOADDITION AND POLYMERS THEREOF | ISP INVESTMENTS INC. (US) | 2016-03-24 | — | — | US | disclosed |
| US-20120041040-A1 | FUNCTIONALIZED 4- AND 5-VINYL SUBSTITUTED REGIOISOMERS OF 1, 2, 3-TRIAZOLES VIA 1, 3-DIPOLAR CYCLOADDITION AND POLYMERS THEREOF | ISP INVESTMENTS INC. (US) | 2012-02-16 | — | — | US | disclosed |
| EP-2358768-A1 | CROSSLINKED POLYVINYLPYRROLIDONE COMPOSITIONS | ISP Investments Inc. (US) | 2011-08-24 | — | — | EP | disclosed |
| WO-2010065603-A1 | CROSSLINKED POLYVINYLPYRROLIDONE COMPOSITIONS | ISP INVESTMENTS INC. (US) | 2010-06-10 | — | — | WO | disclosed |
| EP-2106257-A2 | COMPOSITIONS FOR PROVIDING COLOR TO ANIMATE OBJECTS AND RELATED METHODS | PPG Industries Ohio, Inc. (US) | 2009-10-07 | — | — | EP | disclosed |
| WO-2008091916-A2 | COMPOSITIONS FOR PROVIDING COLOR TO ANIMATE OBJECTS AND RELATED METHODS | PPG INDUSTRIES OHIO, INC. (US) | 2008-07-31 | — | — | WO | disclosed |
| EP-1054865-A1 | FARNESYL TRANSFERASE INHIBITORS | AstraZeneca UK Limited (GB) | 2000-11-29 | — | — | EP | disclosed |
| WO-1999041235-A1 | FARNESYL TRANSFERASE INHIBITORS | ASTRAZENECA UK LIMITED (GB) | 1999-08-19 | — | — | WO | disclosed |
| EP-0820229-A2 | FUNGICIDAL COMPOSITIONS FOR THE ENHANCEMENT OF TURF QUALITY | RHONE-POULENC INC. (US) | 1998-01-28 | — | — | EP | disclosed |
| WO-1996032010-A2 | FUNGICIDAL COMPOSITIONS FOR THE ENHANCEMENT OF TURF QUALITY | RHONE-POULENC, INC. (US) | 1996-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120041040-A1 | FUNCTIONALIZED 4- AND 5-VINYL SUBSTITUTED REGIOISOMERS OF 1, 2, 3-TRIAZOLES VIA 1, 3-DIPOLAR CYCLOADDITION AND POLYMERS THEREOF | ADH5, ADH1A, ADH1C | FOLH1 4400/4885CYP19A1 2564/4885CYP1A1 14/4885 |
| US-20190352271-A1 | MCL-1 INHIBITORS | MCL1, BCL2L1, BCL2 | FOLH1 3149/4885CYP19A1 4463/4885CYP1A1 4066/4885 |
| US-10703733-B2 | MCL-1 inhibitors | MCL1, BCL2L1, BCL2 | FOLH1 3149/4885CYP19A1 4463/4885CYP1A1 4066/4885 |
| US-20160083356-A1 | FUNCTIONALIZED 4- AND 5-VINYL SUBSTITUTED REGIOISOMERS OF 1, 2, 3-TRIAZOLES VIA 1, 3- DIPOLAR CYCLOADDITION AND POLYMERS THEREOF | ADH5, ADH1A, ADH1C | FOLH1 4400/4885CYP19A1 2564/4885CYP1A1 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.